Corvus Pharmaceuticals, Inc. (CRVS) Institutional Ownership

Ownership Summary

A total of 119 institutions have reported a stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) as of December 2025, according to recent 13F filings with the SEC.

• Institutional ownership in Corvus Pharmaceuticals edged up to 55.1% in December 2025, compared to 49.3% in September 2025.
• Quarterly data indicates a 13.09% shift in institutional share volume, and the annual owner count reflects an increase of 36.78%.
• Among the 119 institutional holders of Corvus Pharmaceuticals, 70 added to their stakes while 27 trimmed their positions and 22 held steady.
• The aggregate institutional position in Corvus Pharmaceuticals now stands at 46.66Mn shares as of December 2025, after investors increased their holdings (up by 5.40Mn shares quarter on quarter which is up 7.37Mn shares year over year).
• With 7.17Mn shares, ORBIMED ADVISORS LLC commands the largest institutional position in Corvus Pharmaceuticals as of December 31, 2025, equating to 8.47% of the company.
• Among the most significant buyers of Corvus Pharmaceuticals during December 2025 were MORGAN STANLEY (2.95Mn), MPM BioImpact LLC (2.74Mn), STATE STREET CORP (1.78Mn), DCF Advisers, LLC (729.00K), MILLENNIUM MANAGEMENT LLC (688.77K).
• Leading sellers of Corvus Pharmaceuticals stock in December 2025 included Point72 Asset Management, L.P. (3.58Mn), RTW INVESTMENTS, LP (2.23Mn), PERCEPTIVE ADVISORS LLC (746.15K), GSA CAPITAL PARTNERS LLP (387.22K), Foresite Capital Management VI LLC (350.00K).
• The top 10 institutional holders of Corvus Pharmaceuticals for the quarter ending December 2025 included ORBIMED ADVISORS LLC (7.17Mn), BlackRock, Inc. (5.06Mn), VANGUARD GROUP INC (3.87Mn), MORGAN STANLEY (3.57Mn), ADAMS STREET PARTNERS LLC (3.28Mn), Point72 Asset Management, L.P. (2.88Mn), STATE STREET CORP (2.79Mn), MPM BioImpact LLC (2.74Mn), Vivo Capital, LLC (2.23Mn), GEODE CAPITAL MANAGEMENT, LLC (1.47Mn).